| Name | Title | Contact Details |
|---|
Care Solace is a social purpose organization founded with the mission to implement systemic solutions for sustainable, equitable access to mental health care. Providing a human and technology approach, Care Solace navigates the mental health care system and finds the right help for everyone in every community regardless of coverage, including private insurance, Medicaid, and sliding scale options for those without insurance. We match individuals to more than 350,0000 verified providers, perform a Warm Handoff®, and follow-up on care. Care Solace expands on existing social programs and employer EAPs and bridges the gaps for needs that exceed the scope of those services. Founded in 2017, Care Solace has proudly completed over 6.5 million support interactions across 600 organizations nationwide.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.